AKT1 and hepatocellular carcinoma: Despite an initial significant response to prolong overall survival in HCC patients, resistance to sorafenib via several escape or compensatory mechanisms including activation PI3K/Akt or Met signaling were reported before [9,26,27,28,29,30,31].